Literature DB >> 36247903

Freezing of Gait as a Complication of Pallidal Deep Brain Stimulation in DYT-KMT2B Patients with Evidence of Striatonigral Degeneration.

Laura Cif1, Diane Demailly1, Xavier Vasques2,3, Delphine de Verbizier4, Philippe Coubes1, Kathleen Gorman5,6, Manju A Kurian5,6.   

Abstract

Entities:  

Keywords:  DaTscan; KMT2B; deep brain stimulation; freezing of gait

Year:  2022        PMID: 36247903      PMCID: PMC9547127          DOI: 10.1002/mdc3.13519

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


× No keyword cloud information.
Mutations in KMT2B were first identified in individuals with early‐onset complex dystonia. Since then, it is emerging as one of the most common causes of genetic childhood‐onset dystonia. Additional features include short stature, dysmorphism, developmental delay, psychiatric features, endocrinopathy and others. Patients with DYT‐KMT2B refractory generalized dystonia maintain significant benefit from internal globus pallidus deep brain stimulation (GPi‐DBS) therapy as previously reported, except for laryngeal dystonia and gait. We wish to contribute our observation of freezing of gait (FOG) in KMT2B‐related dystonia by reporting five subjects (four females) with protein truncating variants (PTV) (Table 1).
TABLE 1

Genotype, demographics, age at dystonia onset, at freezing of gait (FOG) and at DBS insertion and follow‐up with DBS

Subject ^ Variant inheritanceCurrent age sexDystonia onset (yr)Dystonia at onset ➔ evolutionAge at GPi DBS (yr) FU with DBS (yr)Age FOG (yr) post‐DBS FOG (yr)Age at DaTscan (yr)DaTscan index/descriptiveDaTscan/MRI

1

9

c.1656dupC

p.Lys553Glnfs*46

de novo

29.5

F

3LL dystonia ➔ generalized dystonia with cranial, cervical & laryngeal

5

23

20.5

15.5

17

Right:

St: 2.46

Pu: 2.47

Cau: 3.02

Bilateral short putamen

Left:

St: 2.23

Pu: 2.15

Cau: 2.61

2

10

c.2137dupA

p.Thr713Asnfs*4

Absent in mother

33

F

3LL dystonia ➔ generalized dystonia with cranial, cervical & laryngeal

8

24

14

6

33

Right:

St: 1.8

Pu: 1.2

Cau: 2.5

Bilateral putaminal hypofixation

Left:

St: 2

Pu: 1.3

Cau: 2.8

3

17

c.3147_3160 del

p.Gly1050Profs*33

Inherited from symptomatic mother

33.5

M

4Laryngeal dystonia ➔ LL, laryngeal & cervical

23

10

24

1

20.5

Right:

St: 2.87

Pu: 2.75

Cau: 3.08

Normal

Left:

St: 3.05

Pu: 3.19

Cau: 3.04

4

21

c.3642 + 5G > A

de novo

45

F

6LL dystonia ➔ generalized dystonia with cranial, cervical & laryngeal

28

17.5

NA

NA

45

Right:

St: 1.9

Pu: 1.6

Cau: 2.3

Bilateral short putamen

Left:

St: 2

Pu: 2.1

Cau: 2.2

5

37

c.6439C > T

p.Gln2147*

de novo

45

F

2LL dystonia ➔ generalized dystonia with cranial, cervical & laryngeal

37

8.5

43

6

36

Right:

St: 1.87

Pu: 1.87

Cau: 2.29

Bilateral short putamen

Left:

St: 1.87

Pu: 1.91

Cau: 2.18

SPECT for 123Ioflupane (DaTscan) imaging and MRI.

Refers to number in Cif et al.

Abbreviations: Cau, Caudate; F, female; LL, lower limb; M, male; Pu, putamen; St, striatum. NA‐not able to walk since severe feet deformities.

Genotype, demographics, age at dystonia onset, at freezing of gait (FOG) and at DBS insertion and follow‐up with DBS 1 9 c.1656dupC p.Lys553Glnfs*46 de novo 29.5 F 5 23 20.5 15.5 Right: St: 2.46 Pu: 2.47 Cau: 3.02 Bilateral short putamen Left: St: 2.23 Pu: 2.15 Cau: 2.61 2 10 c.2137dupA p.Thr713Asnfs*4 Absent in mother 33 F 8 24 14 6 Right: St: 1.8 Pu: 1.2 Cau: 2.5 Bilateral putaminal hypofixation Left: St: 2 Pu: 1.3 Cau: 2.8 3 17 c.3147_3160 del p.Gly1050Profs*33 Inherited from symptomatic mother 33.5 M 23 10 24 1 Right: St: 2.87 Pu: 2.75 Cau: 3.08 Normal Left: St: 3.05 Pu: 3.19 Cau: 3.04 4 21 c.3642 + 5G > A de novo 45 F 28 17.5 NA NA Right: St: 1.9 Pu: 1.6 Cau: 2.3 Bilateral short putamen Left: St: 2 Pu: 2.1 Cau: 2.2 5 37 c.6439C > T p.Gln2147* de novo 45 F 37 8.5 43 6 Right: St: 1.87 Pu: 1.87 Cau: 2.29 Bilateral short putamen Left: St: 1.87 Pu: 1.91 Cau: 2.18 SPECT for 123Ioflupane (DaTscan) imaging and MRI. Refers to number in Cif et al. Abbreviations: Cau, Caudate; F, female; LL, lower limb; M, male; Pu, putamen; St, striatum. NA‐not able to walk since severe feet deformities. Clinical presentation and response to DBS was previously reported. The mean age at dystonia onset was 3.6 years (range: 2–6 years). The median age at DBS implant was 23 years (IQR: 8–30.3 years), and patients were followed for a median of 14.5 years (IQR: 8.5–24 years) after DBS. As illustrated in the Videos 1, 2, and 3, FOG was documented in all, occurring from 14–43 years of age (range: 1–15.5 years after GPi‐DBS). DaTscan (SPECT for 123I‐ioflupane) was abnormal in 4/5 patients undertaken from 2.5 years before, to 24 years after DBS insertion (Table 1). Subject 3, despite normal DaTscan at age 20.5 years (2.5 years pre‐DBS), exhibited mild FOG when turning with lower limb dystonia from 1 year after DBS insertion. DaTscan repeated 13 years later in subject 3 identified bilateral decrease of putaminal uptake. Prior to DBS, dystonia was unresponsive to l‐dopa in all subjects, as was FOG post‐DBS in 2/5. Only 1/5 has maintained independent gait at last follow‐up, despite 4/5 having recovered autonomous gait at steady state under DBS.
VIDEO 1

Freezing of gait (FOG) in DYT‐KMT2B under GPi‐DBS. Subject 1 in the manuscript: The two video sequences (S1, S2) are post‐DBS. Sequence 1 documents FOG as a persistent feature despite adjustment of DBS settings at age 20.5 and sequence 2 age 29.5 years respectively, 15 and 24 years after DBS initiation. Subject 2 in the manuscript: The two video sequences (S3, S4) are recorded post operatively, under DBS. Sequence 3 documents FOG at age 14 and sequence 4 at age 31 respectively, 6 and 17 years after DBS initiation.

VIDEO 2

Video sequences for the patients included in the manuscript illustrating gait previous to the occurrence of FOG. Sequence 1: illustrates subject 1 from the manuscript, early after DBS insertion; lower limbs dystonia is improved compared to preoperative assessment, allowing standing and walking; gait is still impaired by residual dystonia, but the patient does not present yet FOG; the two first video sequences from Video 1 illustrate the occurrence and worsening of FOG over time under DBS for the patient. Sequences 2 and 3: illustrate subject 4 from the manuscript, pre‐DBS and with DBS, respectively. Despite obvious significant improvement of her dystonia under DBS, she was unable to walk because of severe skeletal deformities involving the lower limbs. Sequences 4, 5 and 6: illustrate subject 5 from the manuscript, pre‐DBS and after DBS insertion, before the occurrence of FOG. In sequence 4 (pre‐DBS), gait is very unsteady because of severe dystonia involving trunk and lower limbs; sequence 5 documents significant improvement under DBS, without FOG. Sequence 6 shows altered cadence with mild FOG at turn around.

VIDEO 3

Additional subjects (not included in the manuscript): Subject 1: four consecutive video sequences document gait evolution after DBS; gait was not available pre‐DBS since she was in Status Dystonicus; just after DBS insertion, she was still wheelchair bound, unable to stand and to walk; lower limb dystonia improved allowing standing and gait with support, without FOG. Subject 2: two consecutive video sequences are presented; the first sequence documents dystonic features involving lower limbs during gait pre‐DBS; the second sequence shows occurrence of FOG early after DBS insertion.

Freezing of gait (FOG) in DYT‐KMT2B under GPi‐DBS. Subject 1 in the manuscript: The two video sequences (S1, S2) are post‐DBS. Sequence 1 documents FOG as a persistent feature despite adjustment of DBS settings at age 20.5 and sequence 2 age 29.5 years respectively, 15 and 24 years after DBS initiation. Subject 2 in the manuscript: The two video sequences (S3, S4) are recorded post operatively, under DBS. Sequence 3 documents FOG at age 14 and sequence 4 at age 31 respectively, 6 and 17 years after DBS initiation. Video sequences for the patients included in the manuscript illustrating gait previous to the occurrence of FOG. Sequence 1: illustrates subject 1 from the manuscript, early after DBS insertion; lower limbs dystonia is improved compared to preoperative assessment, allowing standing and walking; gait is still impaired by residual dystonia, but the patient does not present yet FOG; the two first video sequences from Video 1 illustrate the occurrence and worsening of FOG over time under DBS for the patient. Sequences 2 and 3: illustrate subject 4 from the manuscript, pre‐DBS and with DBS, respectively. Despite obvious significant improvement of her dystonia under DBS, she was unable to walk because of severe skeletal deformities involving the lower limbs. Sequences 4, 5 and 6: illustrate subject 5 from the manuscript, pre‐DBS and after DBS insertion, before the occurrence of FOG. In sequence 4 (pre‐DBS), gait is very unsteady because of severe dystonia involving trunk and lower limbs; sequence 5 documents significant improvement under DBS, without FOG. Sequence 6 shows altered cadence with mild FOG at turn around. Additional subjects (not included in the manuscript): Subject 1: four consecutive video sequences document gait evolution after DBS; gait was not available pre‐DBS since she was in Status Dystonicus; just after DBS insertion, she was still wheelchair bound, unable to stand and to walk; lower limb dystonia improved allowing standing and gait with support, without FOG. Subject 2: two consecutive video sequences are presented; the first sequence documents dystonic features involving lower limbs during gait pre‐DBS; the second sequence shows occurrence of FOG early after DBS insertion. Feuerstein et al. reported on the emergence of parkinsonism and abnormal brain DaTscan imaging in a patient with a heterozygous loss‐of‐function KMT2B variant (c.974_979del, p.Ser325*). He presented at aged 3 years with typical features of DYT‐KMT2B, necessitating GPi‐DBS aged 23 years. Though, initial benefit was evident, by 33 years, generalized dystonia, parkinsonism with rigidity, bradykinesia and FOG predominated. Extensive DBS reprogramming and switch‐off did not modify symptoms. DaTscan showed bilateral decreased putaminal uptake. In this patient, Rotigotine (but not l‐dopa) significantly improved FOG. In our DYT‐KMT2B group, FOG occurred across a broad age range, from an early post‐operative presentation to more than 15 years after DBS insertion. All patients had PTVs. In a previous publication, in DYT‐KMT2B, dystonia severity scores appeared to be comparable and more severe in PTVs and chromosomal deletions versus missense variants, possibly suggestive of a relationship between motor severity and type of KMT2B variant. To date, FOG has not been reported in patients with missense variants; identification of further cases will determine whether this is a true genotype–phenotype correlation. Many dystonia‐parkinsonism disorders are associated with reduced striatal dopamine due to degeneration of substantia nigra pars compacta neurons. Our finding of bilateral short putamen on DaTscan is suggestive of striatal dopaminergic denervation in DYT‐KMT2B. Contrary to levodopa‐induced dyskinesia and wearing‐off phenomena in Parkinson's disease (PD), the pattern of striatal dopamine depletion does not seem to affect the risk of FOG in PD. Nevertheless, in de novo PD patients, those with severe reduction of DaT uptake in the caudate and putamen have a significantly higher incidence of FOG than those with mild or moderate uptake reduction. Therefore, it is possible that the specific striatal anatomy and reduced dorsolateral (motor) putaminal DaT uptake in DYT‐KMT2B patients could potentially propagate network alterations to drive the DBS‐mediated switch to hypokinesia, despite ongoing therapeutic effect for dystonia. The relationship between DYT‐KMT2B, FOG and DBS intervention remains yet to be fully elucidated; nevertheless, and contrary to other monogenic dystonias, in DYT‐KMT2B, DaTscan abnormalities and FOG is an emerging phenomenon, at least in those patients with PTVs. Long‐term GPi‐DBS is reported to lead to hypokinetic gait disorders in patients treated for dystonia. In DYT‐TOR1A, physiological parameters such as the paired associative stimulation response were almost absent and short‐interval intracortical inhibition reduced. This pattern, resembles untreated PD may in part explain the observed hypokinesia in DBS‐treated dystonia without abnormal DaTscan imaging. In conclusion, the potential risk of hypokinetic gait disorders in DYT‐KMT2B should be considered in patients undergoing GPi‐DBS, which warrants strict monitoring of the motor phenomenology post‐procedure. Serial DaT SPECT imaging may aid identification of striatal dopaminergic denervation in DYT‐KMT2B and a clinical trial of levodopa or dopaminergic agonist may be useful. More evidence is needed to improve understanding of the etiological basis and efficacy of different interventions for DYT‐KMT2B‐related hypokinetic movement disorders.

Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the first draft, B. Review and Critique. LC: 1A, 1B, 1C, 2A, 2C, 3A, 3B. DD: 1C, 2C, 3B. XV: 1C, 2B, 2C, 3B. DDV: 1C, 2C, 3C. PC: 1C, 2C, 3C. KG: 1A, 1C, 2B, 2C, 3A, 3B. MAK: 1A, 1C, 2B, 2C, 3A, 3B.

Disclosures

Ethical Compliance Statement

The study was approved by the Internal Review Board of Montpellier University Hospital (Ethics Board number 2018_IRB‐MTP_11–11). Written informed consent was obtained for all participants in whom research genetic testing was undertaken and for publication of videos. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest

No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months

L.C., D.D., X.V., D.D.V., P.C., K.G. and M.A.K. declare that there are no additional disclosures to report.
  9 in total

1.  Shaping reversibility? Long-term deep brain stimulation in dystonia: the relationship between effects on electrophysiology and clinical symptoms.

Authors:  Diane Ruge; Laura Cif; Patricia Limousin; Victoria Gonzalez; Xavier Vasques; Marwan I Hariz; Philippe Coubes; John C Rothwell
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

2.  Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort.

Authors:  Ryul Kim; Joongyub Lee; Yoon Kim; Aryun Kim; Mihee Jang; Han-Joon Kim; Beomseok Jeon; Un Jung Kang; Stanley Fahn
Journal:  Parkinsonism Relat Disord       Date:  2018-02-28       Impact factor: 4.891

3.  Patterns of striatal dopamine depletion in early Parkinson disease: Prognostic relevance.

Authors:  Seok Jong Chung; Hye Sun Lee; Han Soo Yoo; Yang Hyun Lee; Phil Hyu Lee; Young H Sohn
Journal:  Neurology       Date:  2020-07-02       Impact factor: 9.910

4.  Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.

Authors:  Esther Meyer; Keren J Carss; Julia Rankin; John M E Nichols; Detelina Grozeva; Agnel P Joseph; Niccolo E Mencacci; Apostolos Papandreou; Joanne Ng; Serena Barral; Adeline Ngoh; Hilla Ben-Pazi; Michel A Willemsen; David Arkadir; Angela Barnicoat; Hagai Bergman; Sanjay Bhate; Amber Boys; Niklas Darin; Nicola Foulds; Nicholas Gutowski; Alison Hills; Henry Houlden; Jane A Hurst; Zvi Israel; Margaret Kaminska; Patricia Limousin; Daniel Lumsden; Shane McKee; Shibalik Misra; Shekeeb S Mohammed; Vasiliki Nakou; Joost Nicolai; Magnus Nilsson; Hardev Pall; Kathryn J Peall; Gregory B Peters; Prab Prabhakar; Miriam S Reuter; Patrick Rump; Reeval Segel; Margje Sinnema; Martin Smith; Peter Turnpenny; Susan M White; Dagmar Wieczorek; Sarah Wiethoff; Brian T Wilson; Gidon Winter; Christopher Wragg; Simon Pope; Simon J H Heales; Deborah Morrogh; Alan Pittman; Lucinda J Carr; Belen Perez-Dueñas; Jean-Pierre Lin; Andre Reis; William A Gahl; Camilo Toro; Kailash P Bhatia; Nicholas W Wood; Erik-Jan Kamsteeg; Wui K Chong; Paul Gissen; Maya Topf; Russell C Dale; Jonathan R Chubb; F Lucy Raymond; Manju A Kurian
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

5.  Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.

Authors:  Miryam Carecchio; Federica Invernizzi; Paulina Gonzàlez-Latapi; Celeste Panteghini; Giovanna Zorzi; Luigi Romito; Vincenzo Leuzzi; Serena Galosi; Chiara Reale; Federica Zibordi; Agnel P Joseph; Maya Topf; Carla Piano; Anna Rita Bentivoglio; Floriano Girotti; Paolo Morana; Benedetto Morana; Manju A Kurian; Barbara Garavaglia; Niccolò E Mencacci; Steven J Lubbe; Nardo Nardocci
Journal:  Mov Disord       Date:  2019-06-19       Impact factor: 10.338

6.  GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia.

Authors:  C Schrader; H-H Capelle; T M Kinfe; C Blahak; H Bäzner; G Lütjens; D Dressler; J K Krauss
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

7.  Parkinsonism and Positive Dopamine Transporter Imaging in a Patient with a Novel KMT2B Variant.

Authors:  Jeanne S Feuerstein; Matthew Taylor; Jennifer J Kwak; Brian D Berman
Journal:  Mov Disord Clin Pract       Date:  2021-02-02

Review 8.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

9.  KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation.

Authors:  Laura Cif; Diane Demailly; Jean-Pierre Lin; Katy E Barwick; Mario Sa; Lucia Abela; Sony Malhotra; Wui K Chong; Dora Steel; Alba Sanchis-Juan; Adeline Ngoh; Natalie Trump; Esther Meyer; Xavier Vasques; Julia Rankin; Meredith W Allain; Carolyn D Applegate; Sanaz Attaripour Isfahani; Julien Baleine; Bettina Balint; Jennifer A Bassetti; Emma L Baple; Kailash P Bhatia; Catherine Blanchet; Lydie Burglen; Gilles Cambonie; Emilie Chan Seng; Sandra Chantot Bastaraud; Fabienne Cyprien; Christine Coubes; Vincent d'Hardemare; Asif Doja; Nathalie Dorison; Diane Doummar; Marisela E Dy-Hollins; Ellyn Farrelly; David R Fitzpatrick; Conor Fearon; Elizabeth L Fieg; Brent L Fogel; Eva B Forman; Rachel G Fox; William A Gahl; Serena Galosi; Victoria Gonzalez; Tracey D Graves; Allison Gregory; Mark Hallett; Harutomo Hasegawa; Susan J Hayflick; Ada Hamosh; Marie Hully; Sandra Jansen; Suh Young Jeong; Joel B Krier; Sidney Krystal; Kishore R Kumar; Chloé Laurencin; Hane Lee; Gaetan Lesca; Laurence Lion François; Timothy Lynch; Neil Mahant; Julian A Martinez-Agosto; Christophe Milesi; Kelly A Mills; Michel Mondain; Hugo Morales-Briceno; John R Ostergaard; Swasti Pal; Juan C Pallais; Frédérique Pavillard; Pierre-Francois Perrigault; Andrea K Petersen; Gustavo Polo; Gaetan Poulen; Tuula Rinne; Thomas Roujeau; Caleb Rogers; Agathe Roubertie; Michelle Sahagian; Elise Schaefer; Laila Selim; Richard Selway; Nutan Sharma; Rebecca Signer; Ariane G Soldatos; David A Stevenson; Fiona Stewart; Michel Tchan; Ishwar C Verma; Bert B A de Vries; Jenny L Wilson; Derek A Wong; Raghda Zaitoun; Dolly Zhen; Anna Znaczko; Russell C Dale; Claudio M de Gusmão; Jennifer Friedman; Victor S C Fung; Mary D King; Shekeeb S Mohammad; Luis Rohena; Jeff L Waugh; Camilo Toro; F Lucy Raymond; Maya Topf; Philippe Coubes; Kathleen M Gorman; Manju A Kurian
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.